logo-loader
Ashtead Group

Ashtead Group boosted by UBS upgrade to ‘neutral’ from ‘sell’ on valuation grounds after big de-rating

The Swiss bank also raised its price target for the FTSE 100-listed firm to 1,800p from 1,700p, with the stock currently changing hands at 1,814.50p, up 3.5% on Monday’s close

Equipment hire truck
UBS's analysts said, given the de-rating by Ashtead, the risk/reward for the stock looks balanced

UBS gave a boost to Ashtead Group PLC (LON:AHT) on Tuesday, upgrading its rating for the equipment hire firm to ‘neutral’ from ‘sell’ on valuation grounds.

The Swiss bank also raised its price target for the FTSE 100-listed firm to 1,800p from 1,700p, with the stock currently changing hands at 1,814.50p, up 3.5% on Monday’s close.

READ: Ashtead predicts forecast-beating annual profit after US growth boosts first half

In a note to clients, the UBS analysts said: “Although Ashtead's performance has been significantly ahead of our original Sell thesis the shares have fallen c35% since early-cycle data started to deteriorate in Aug-18.”

They pointed out that risks appear to be rising, with predictions of a shallow industrial downturn ahead similar to that seen in 2015/16, and evidence of weakening rental demand and rising supply.

The analysts said: “Ashtead continues to take share and drive penetration gains, but we expect underlying volume growth to slow into high-single digits over the next 12mths”.

However, they added, given the de-rating by Ashtead to a Price Earnings (PE) of around 9 times, in line with the 2015 trough, the risk/reward for the stock looks balanced.

The analysts forecast that a deeper downturn could see Ashtead shares drop by 27%, while a more limited impact of economic disruption could see the stock jump 34%. 

Quick facts: Ashtead Group

Price: £21.30

Market: LSE
Market Cap: £9.84 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan PLC targeting 'value creation and rapid scale-up'

Proactive Research analyst Emma Ulker discusses the opportunity with Open Orphan PLC (LON:ORPH). She says the firm's targeting value creation and rapid scale-up via acquisitions in the orphan and rare drugs market - a space which is growing at around 11% a year. Ulker adds they're looking...

4 hours ago

2 min read